CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities:
Net loss	$ (20,722)	$ (12,968)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,454	1,785
Stock-based compensation	3,568	1,612
Amortization of debt discount and debt issuance costs	1,238	503
Amortization of right-of-use asset	259	217
Provision for doubtful accounts	(5)	66
Provision for excess and obsolete inventory	1,722	1,997
Deferred income tax benefit		4
Beneficial conversion feature from convertible notes		242
Loss (Gain) on disposal of instruments	32	(275)
Accretion to contingent consideration		289
Changes in operating assets and liabilities:
Accounts receivable, net	782	1,268
Inventories, net	(4,741)	(4,398)
Prepaid expenses and other current assets	(983)	198
Other assets		69
Other long-term assets		(2,612)
Accrued expenses and other	(2,643)	(1,071)
Accounts payable	3,414	3,319
Lease liability	(324)	2,910
Other long-term liabilities	(1,099)	(1,099)
Net cash used in operating activities	(17,048)	(7,944)
Investing activities:
Purchases of property and equipment	(2,629)	(1,068)
Net cash used in investing activities	(2,629)	(1,068)
Financing activities:
Proceeds from sale of common stock, net	833	14
Borrowings under lines of credit	29,544	26,433
Repayments under lines of credit	(30,408)	(26,822)
Principal payments on capital lease obligations	(8)	(5)
Debt issuance costs		(300)
Principal payments on term loan and notes payable		(3,022)
Net cash used in financing activities	(39)	(3,702)
Effect of exchange rate changes on cash	69	79
Net decrease in cash	(19,647)	(12,635)
Cash at beginning of period, including discontinued operations	47,113	29,054
Cash at end of period, including discontinued operations	27,466	16,419
Supplemental disclosure of cash flow information:
Cash paid for interest	1,646	1,357
Cash paid for income taxes	25	23
Supplemental disclosure of noncash investing and financing activities:
Purchases of property and equipment in accounts payable	$ 1,297	785
SafeOp Surgical, Inc.
Supplemental disclosure of noncash investing and financing activities:
Common stock issued for achievement of SafeOp contingent consideration		$ 2,889